|drug2263||Norovirus Bivalent (GI.1 / GII.4) Vaccine（low） Wiki||0.45|
|drug2264||Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle） Wiki||0.45|
|drug218||Aluminum adjuvant Wiki||0.45|
|drug2746||Questionnaire forms Wiki||0.45|
|drug2262||Norovirus Bivalent (GI.1 / GII.4) Vaccine（high） Wiki||0.45|
|drug951||Current care per UCLA treating physicians Wiki||0.45|
|drug2615||Povidone-Iodine Nasal Spray and Gargle Wiki||0.32|
|drug832||Colchicine Tablets Wiki||0.22|
|D017250||Caliciviridae Infections NIH||0.32|
|D002055||Burnout, Professional NIH||0.18|
|D000077062||Burnout, Psychological NIH||0.12|
|D018352||Coronavirus Infections NIH||0.05|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.04|
|D055371||Acute Lung Injury NIH||0.04|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.04|
There are 5 clinical trials
This trial investigates whether clazakizumab (an anti-interleukin (IL)-6 monoclonal antibody (mAb)) may be beneficial for the treatment of CABMR in recipients of a kidney transplant by inhibiting the production of Donor Specific Antibodies (DSA) and re-shaping T cell alloimmune responses.
Description: The aim of this study is to follow enrolled participants until 221 occurrences of all-cause allograft loss, defined as return to dialysis, allograft nephrectomy, re-transplantation, eGFR <15 mL/min/1.73 m2 or death from any cause have been observed. The analysis will be a stratified log rank test of the effect of treatment on all-cause composite allograft loss, with stratification factors of dichotomized baseline eGFR (25-45 mL/min/1.73 m2 versus >45-65 mL/min/1.73 m2), baseline proteinuria, treatment for early (within 6 months of transplant) ABMR rejection episodes (yes/no), and treatment for late (greater than 6 months post transplant) ABMR rejection episodes (yes/no). Surviving subjects without allograft loss will be censored at the time of their last assessment.Measure: Incidence of all cause composite allograft loss Time: Five years
A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.
Description: Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccinationMeasure: All active AEs within 0-7 days after each dose Time: 7 days
Description: Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time windowMeasure: All non-active collection AEs within 0-28（30） days after each dose Time: 28（30） days
This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.
Description: Percentage of subjects discharged from hospital without the need for intubation and mechanical ventilationMeasure: Percentage of patients discharged from the hospital alive and without the need for mechanical ventilation. Time: Variable up to Day 28
Description: 25% change (decrease) in noted baseline elevations of serum ferritin, LDH, CRP, and d-dimer.Measure: Percentage of subjects with 25% change (decrease) in cytokine storm markers at 48 hours Time: 48 hours
Description: Supplemental oxygen requirement to maintain oxygen saturation >90% stable or decreased without escalation of respiratory support measures (addition of CPAP, initiation of mechanical ventilation)Measure: Percentage of subjects without increase in oxygen requirement and no increase in oxygen delivery/respiratory support measures after 48 hours. Time: Day 2 (48 hours)-Day 10 (240 hours)
Description: Time from initial dosing of IP to achievement of ≥93% oxygen saturation on room air for 24 hoursMeasure: Average time in days to achieve sustained ≥93% oxygen saturation without oxygen/respiratory support Time: 0-10 days
Description: Normalization or ≥ 75% improvement by Day 10 (120 hours) in each of the following laboratory CSS attributes elevated beyond the normal range at randomization: ferritin, fibrinogen, AST, ALT, leucopenia, thrombocytopenia, d-dimer, CRP, triglycerides, sCD25.Measure: Percentage of subjects with resolution of laboratory markers of Cytokine Storm syndrome Time: Day 10
Description: No increased prevalence of bacterial or fungal or viral infection through the time of hospital discharge until Day 28.Measure: Percentage of subjects who develop bacterial or fungal or non-Covid-19 viral infection Time: Day 0-28
Description: No failure to develop neutralizing antibody to Covid-19 measured at Day 28.Measure: Percentage of subjects who develop neutralizing antibody to Covid-19 Time: Day 28
COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that is present in the nose and mouth. This also could mean that there is less virus available to pass on to others. We want to see if the use of nose rinses and mouth washes using Povidone-Iodine will reduce the the amount of virus in the nose and throat of people who have tested positive for COVID-19 disease and also reduce the spread of infection within their household.
Description: viral load as measured by real time polymerase chain reaction (PCR)Measure: Change in viral load in the oral and nasopharyngeal cavity Time: Day 0, 2, 3, 7, 14
Description: Visual analogue score 1-5 per symptom via a smartphone appMeasure: Symptom severity in primary participants and co-residents Time: Days 0 to 14
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.
Description: Incidence and severity of other adverse events and severe adverse events (SAE)Measure: Number of Participants Having Adverse Events Time: 29 Days
Description: transfusion-related adverse eventsMeasure: Number of Participants Having Transfusion-Related Adverse Events Time: 29 Days
Description: Incidence and severity of adverse events and SAEs from Screening through Study Day 90Measure: Number of Participants Having Adverse Events Time: 90 Days
Description: SARS-CoV-2 binding (ELISA) and neutralizing (PRNT80) antibody titers from Screening through Study Day 90Measure: Pharmacokinetics from screening to day 90 Time: 90 Days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports